Novel N, N'-Hydrazino-bis-isatin Derivatives with Selective Activity Against Multidrug-Resistant Cancer Cells
申请人:Mohamed Hassan Tarek Aboul-Fadl
公开号:US20120252860A1
公开(公告)日:2012-10-04
The invention is directed to a compound of Formula (I),
wherein R is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group; R
1
is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group; X is selected from the group consisting of hydrogen atom or halogen atom; and Y is selected from the group consisting of hydrogen atom, halogen atom, C
1
-C
4
alkyl group, nitro group, and —OCF
3
group, as well as for its use in therapy, preferably for the treatment of cancer, and to a related pharmaceutical composition, the use of the compound for the manufacture of a medicament for the respective medical indication, and a method of synthesis of the compounds of the invention.
synthesized by condensation of the natural or synthetic isatins with hydrazine and were evaluated for their in vitro and in vivoantitumor activities. More than half of the obtained compounds showed potent cytotoxicity according to the MTT assay on five different human cancer cell lines (i.e. HeLa, SGC-7901, HepG2, U251, and A549), with compound 3b 3,3′-(hydrazine-1,2-diylidene)bis (5-methylindolin-2-one)